Systemic Chemotherapy Plus PD-1 for Metastasis ICC
Conditions: ICC; Metastatic Cancer Interventions: Drug: Folfirinox; Drug: Sintilimab Sponsor: Sun Yat-sen University Recruiting
Enzalutamide improves 5-year survival in men with chemotherapy-naive metastatic castration-resistant prostate cancer, but increases the risk of fatal adverse events, according to final results from the PREVAIL trial.Reuters Health Information
AbstractObjectivesChemotherapy-induced neutropenia (CIN) is a common adverse event of chemotherapy. Several reports have suggested that CIN could be an important prognostic factor in chemotherapy of various cancers. However, whether CIN is a prognostic factor in unresectable pancreatic cancer (PC) treated with gemcitabine plus nab-paclitaxel (GnP) is unknown. The primary endpoint of this study was to compare overall survival (OS) between patients with severe CIN (grade ≥ 3) and those with absent/mild CIN (grade ≤ 2) in unresectable PC cases treated with GnP as first-line chemotherapy.Meth...
ConclusionsOur retrospective analysis showed that metformin with front-line chemotherapy in diabetic patients resulted in improved PFS and OS. Our pre-clinical studies demonstrate metformin has potential to re-sensitize resistant lymphoma to the chemo-immunotherapy and allow us to develop a hypothesis as to its activity in DLBCL.
ConclusionsSCC in SB can appear at a young age and is usually diagnosed in an advanced tumor stage with poor prognosis despite radical surgical resection. Patients with SB without BA with clinical symptoms, new onset of hematuria, and/or upper tract dilatation should receive a cystoscopy ± further imaging.
We hypothesized that higher Charlson comorbidity index(CCI) predicts worse one-month mortality and overall survival(OS) in patients ≥60 years with acute myeloid leukemia(AML). In our National Cancer Database study, patients with CCI 0 were more likely to receive chemotherapy and undergo upfront hematopoietic cell transplant. One-month mortality and OS were significantly worse with CCI 1 or ≥2, compared to CCI 0.
Conclusion. A combination of chemotherapy and MSC can yield to more favorable results in the treatment of HCC. PMID: 32617114 [PubMed]
Authors: Wongsaengsak S, Quirch M, Ball S, Sultan A, Jahan N, Elmassry M, Rehman S Abstract Docetaxel is an anti-microtubule agent and a highly effective treatment of locally advanced and metastatic breast cancer. There are several adverse effects associated with docetaxel, such as myelosuppression, peripheral neuropathy, fluid retention, and asthenia. One of the most well-known side-effects of this medication is mild to moderate myalgia. Here, we report a case of a 49-year-old female with stage 3 breast cancers who developed severe acute myositis following docetaxel use. The mechanism of docetaxel-induced myositis...
ConclusionThis study demonstrated PK bioequivalence of INTP24 to US-bevacizumab and EU-bevacizumab in healthy male subjects and showed similar safety and immunogenicity profiles across the treatment groups.
A 53-year-old male with history of colon cancer status post neoadjuvant chemotherapy, radiation and colectomy, hyperlipidemia, non-insulin-dependent diabetes mellitus, obesity, hernia repair, and asthma presented to the urology clinic complaining of left inguinal swelling. Upon presentation, vital signs were unremarkable, but physical exam revealed a firm, palpable, nontender abnormality of the left inguinal region. Subsequent CT scan with IV contrast revealed a large presacral fluid collection (7.0 × 2.4 cm) and complex cystic structure arising from the left tunica albuginea (3.8 × 3.0 cm) adjacent to...
In conclusion, our study identified the LAR as an independent prognostic factor in surgically treated pancreatic cancer patients.